{"protocolSection":{"identificationModule":{"nctId":"NCT01134263","orgStudyIdInfo":{"id":"CYD17"},"secondaryIdInfos":[{"id":"U1111-1114-7646","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia","officialTitle":"Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia"},"statusModule":{"statusVerifiedDate":"2019-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-10-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2012-11","type":"ACTUAL"},"completionDateStruct":{"date":"2013-02","type":"ACTUAL"},"studyFirstSubmitDate":"2010-05-27","studyFirstSubmitQcDate":"2010-05-27","studyFirstPostDateStruct":{"date":"2010-05-31","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-21","resultsFirstSubmitQcDate":"2019-05-21","resultsFirstPostDateStruct":{"date":"2019-07-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-05-21","lastUpdatePostDateStruct":{"date":"2019-07-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.\n\nPrimary Objective\n\n* To demonstrate that three different Phase III lots of CYD dengue vaccine induce an equivalent immune response in terms of post-Dose 3 geometric mean titers (GMTs) against the four parental serotypes.\n\nSecondary Objectives:\n\n* To demonstrate that data from one Phase II lot and pooled data from Phase III lots of CYD dengue vaccine show an equivalent immune response in terms of post-Dose 3 GMTs against the four parental serotypes.\n* To describe the safety of the CYD dengue vaccine in all participants after each dose.","detailedDescription":"All participants received 3 doses of their assigned vaccine or placebo and provided blood samples at defined timepoints for flavivirus status and immunogenicity assessment. Safety data were collected in all participants after each dose and throughout the study."},"conditionsModule":{"conditions":["Dengue Fever","Dengue Hemorrhagic Fever"],"keywords":["Dengue Fever","Dengue Hemorrhagic Fever","CYD Dengue Vaccine","Lot Consistency"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","maskingDescription":"An observer-blind procedure was followed for the three injections with CYD dengue vaccine or placebo. Neither the observer, Investigator, Sponsor, nor the participant knew which product was administered.","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":715,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CYD Dengue Vaccine Phase III Lot 1","type":"EXPERIMENTAL","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus"]},{"label":"CYD Dengue vaccine - Phase III Lot 2","type":"EXPERIMENTAL","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus"]},{"label":"CYD Dengue vaccine - Phase III Lot 3","type":"EXPERIMENTAL","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus"]},{"label":"CYD Dengue vaccine - Phase II Lot","type":"EXPERIMENTAL","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","interventionNames":["Biological: Placebo: NaCl 0.9%"]}],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","description":"0.5 ml, Subcutaneous (SC)","armGroupLabels":["CYD Dengue Vaccine Phase III Lot 1"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","description":"0.5 ml, SC","armGroupLabels":["CYD Dengue vaccine - Phase III Lot 2"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","description":"0.5 ml, SC","armGroupLabels":["CYD Dengue vaccine - Phase III Lot 3"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","description":"0.5 ml, Subcutaneous (SC)","armGroupLabels":["CYD Dengue vaccine - Phase II Lot"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: NaCl 0.9%","description":"0.5 ml, SC","armGroupLabels":["Placebo"],"otherNames":["NaCl"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine","description":"GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) assay. The lot-to-lot consistency between 3 Phase III lots was based on the use of the two-sided 95% confidence interval (CI) of the differences of the means of the log10 transformed post-vaccination titers between pairs of lots.","timeFrame":"28 days post-injection 3"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine","description":"GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using PRNT assay. Equivalence of Phase III vaccine with Phase II vaccine was assessed by Bridging between Phase III and Phase II Lot of CYD Dengue Vaccine.","timeFrame":"28 days post-Injection 3"},{"measure":"Number of Participants With Solicited Injection Site Reactions After Any Vaccination","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Pain: Grade 3: Significant; prevents daily activity. Erythema and Swelling: Grade 3: \\> 10 cm. Participants with Injection Site Reactions of any Grade (1, 2 or 3) and grade 3 were reported.","timeFrame":"7 days post any vaccination"},{"measure":"Number of Participants With Solicited Systemic Reactions After Any Vaccination","description":"Solicited systemic reactions: Asthenia, Fever, Headache, Malaise and Myalgia. Fever: Grade 3: \\>=39.0°C (\\>=102.1°F). Headache, malaise, myalgia and asthenia: Grade 3: significant; prevents daily activity. Participants with systemic reactions of any Grade (1, 2 or 3) and grade 3 were reported.","timeFrame":"14 days post any vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 18 to 60 years on the day of inclusion.\n* Informed consent form was signed and dated.\n* Able to attend all scheduled visits and to comply with all trial procedures.\n* For a woman of childbearing potential, use of an effective method of contraception, or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination (i.e., for 14 months).\n\nExclusion Criteria:\n\n* Known pregnancy, or a positive urine pregnancy test.\n* History of flavivirus infection or vaccination or prolonged habitation in a dengue endemic area.\n* Currently breastfeeding a child.\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.\n* Planned participation in another clinical trial during the present trial period.\n* Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except for pandemic influenza vaccination.\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Self-reported seropositivity for human immunodeficiency virus (HIV).\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures.\n* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.\n* Identified as a site employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the site employees or the Investigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Sanofi Pasteur Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Adelaide","zip":"SA 5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"city":"Carina Heights","zip":"QLD 4152","country":"Australia","geoPoint":{"lat":-27.50721,"lon":153.09126}},{"city":"Enoggera","zip":"QLD 4051","country":"Australia","geoPoint":{"lat":-27.42832,"lon":152.97467}},{"city":"Heidelberg","zip":"VIC 3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"city":"Herston","zip":"QLD 4006","country":"Australia","geoPoint":{"lat":-27.44453,"lon":153.01852}},{"city":"Herston","zip":"QLD 4029","country":"Australia","geoPoint":{"lat":-27.44453,"lon":153.01852}},{"city":"Subiaco","zip":"WA 6008","country":"Australia","geoPoint":{"lat":-31.9485,"lon":115.8268}},{"city":"Westmead","zip":"NSW 2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}}]},"referencesModule":{"references":[{"pmid":"26279339","type":"RESULT","citation":"Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, Nissen MD, Richmond PC. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine. 2015 Sep 22;33(39):5127-34. doi: 10.1016/j.vaccine.2015.08.008. Epub 2015 Aug 13."},{"pmid":"28968794","type":"DERIVED","citation":"Torresi J, Richmond PC, Heron LG, Qiao M, Marjason J, Starr-Spires L, van der Vliet D, Jin J, Wartel TA, Bouckenooghe A. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. J Infect Dis. 2017 Oct 17;216(7):834-841. doi: 10.1093/infdis/jix314."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 715 participants who met all of the inclusion criteria and none of the exclusion criteria were enrolled in the study.","recruitmentDetails":"Study participants were enrolled from 05 October 2010 to 26 November 2010 at 8 study sites in Australia.","groups":[{"id":"FG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"FG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"FG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"FG003","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"FG004","title":"Placebo","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"164"},{"groupId":"FG001","numSubjects":"163"},{"groupId":"FG002","numSubjects":"163"},{"groupId":"FG003","numSubjects":"168"},{"groupId":"FG004","numSubjects":"57"}]},{"type":"Received Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"162"},{"groupId":"FG002","numSubjects":"163"},{"groupId":"FG003","numSubjects":"167"},{"groupId":"FG004","numSubjects":"57"}]},{"type":"Received Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"152"},{"groupId":"FG002","numSubjects":"139"},{"groupId":"FG003","numSubjects":"154"},{"groupId":"FG004","numSubjects":"53"}]},{"type":"Received Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"145"},{"groupId":"FG002","numSubjects":"134"},{"groupId":"FG003","numSubjects":"151"},{"groupId":"FG004","numSubjects":"49"}]},{"type":"Safety Population","comment":"Safety Population:All participants who received study drug, analyzed according to treatment received","achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"161"},{"groupId":"FG002","comment":"1 participant randomized to the Phase III Lot 2 group, received Phase III Lot 3 vaccination.","numSubjects":"164"},{"groupId":"FG003","numSubjects":"167"},{"groupId":"FG004","numSubjects":"57"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"143"},{"groupId":"FG002","numSubjects":"134"},{"groupId":"FG003","numSubjects":"149"},{"groupId":"FG004","numSubjects":"48"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"19"},{"groupId":"FG004","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Serious adverse event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Other adverse event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"5"}]},{"type":"Enrolled, but not treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on Full Analysis Set included all participants who received at least 1 injection of CYD Dengue Vaccine or placebo.","groups":[{"id":"BG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"BG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"BG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"BG003","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months, subcutaneously."},{"id":"BG004","title":"Placebo","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"163"},{"groupId":"BG003","value":"167"},{"groupId":"BG004","value":"57"},{"groupId":"BG005","value":"712"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39.4","spread":"13.3"},{"groupId":"BG001","value":"39.4","spread":"12.9"},{"groupId":"BG002","value":"38.7","spread":"14.1"},{"groupId":"BG003","value":"38.4","spread":"13.2"},{"groupId":"BG004","value":"39.7","spread":"13.5"},{"groupId":"BG005","value":"39.0","spread":"13.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"84"},{"groupId":"BG003","value":"84"},{"groupId":"BG004","value":"33"},{"groupId":"BG005","value":"391"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"79"},{"groupId":"BG003","value":"83"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"321"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine","description":"GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) assay. The lot-to-lot consistency between 3 Phase III lots was based on the use of the two-sided 95% confidence interval (CI) of the differences of the means of the log10 transformed post-vaccination titers between pairs of lots.","populationDescription":"Analysis was performed on Per-protocol analysis set which included participants who received at least 1 dose of the study vaccine or placebo and had no protocol deviations. Data for this outcome measure was not planned to be collected and analyzed for Phase II Lot and placebo.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer (1/dilution)","timeFrame":"28 days post-injection 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month12 (vaccination 3), subcutaneously."},{"id":"OG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month12 (vaccination 3) , subcutaneously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"124"}]}],"classes":[{"title":"Dengue Virus Serotype 1","categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"16.9","upperLimit":"25.1"},{"groupId":"OG001","value":"18.1","lowerLimit":"14.8","upperLimit":"22.2"},{"groupId":"OG002","value":"17.1","lowerLimit":"13.9","upperLimit":"21.2"}]}]},{"title":"Dengue Virus Serotype 2","categories":[{"measurements":[{"groupId":"OG000","value":"65.9","lowerLimit":"50.6","upperLimit":"85.7"},{"groupId":"OG001","value":"44.1","lowerLimit":"33.3","upperLimit":"58.3"},{"groupId":"OG002","value":"58.1","lowerLimit":"43.2","upperLimit":"78.2"}]}]},{"title":"Dengue Virus Serotype 3","categories":[{"measurements":[{"groupId":"OG000","value":"74.2","lowerLimit":"60.1","upperLimit":"91.7"},{"groupId":"OG001","value":"65","lowerLimit":"53.2","upperLimit":"79.3"},{"groupId":"OG002","value":"71.6","lowerLimit":"58.2","upperLimit":"88.2"}]}]},{"title":"Dengue Virus Serotype 4","categories":[{"measurements":[{"groupId":"OG000","value":"131.8","lowerLimit":"101.4","upperLimit":"171.3"},{"groupId":"OG001","value":"94.6","lowerLimit":"75.3","upperLimit":"118.7"},{"groupId":"OG002","value":"108.5","lowerLimit":"84.2","upperLimit":"139.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 1: Phase III Lot 1 vs Lot 2","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.055","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.067","ciUpperLimit":"0.178"},{"groupIds":["OG001","OG002"],"groupDescription":"Dengue Virus Serotype 1: Phase III Lot 2 vs Lot 3","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.024","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.102","ciUpperLimit":"0.151"},{"groupIds":["OG000","OG002"],"groupDescription":"Dengue Virus Serotype 1: Phase III Lot 3 vs Lot 1","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.080","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.204","ciUpperLimit":"0.045"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 2: Phase III Lot 1 vs Lot 2","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.174","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.009","ciUpperLimit":"0.340"},{"groupIds":["OG001","OG002"],"groupDescription":"Dengue Virus Serotype 2: Phase III Lot 2 vs Lot 3","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.120","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.297","ciUpperLimit":"0.056"},{"groupIds":["OG000","OG002"],"groupDescription":"Dengue Virus Serotype 2: Phase III Lot 3 vs Lot 1","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.054","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.225","ciUpperLimit":"0.117"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 3: Phase III Lot 1 vs Lot 2","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.058","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.068","ciUpperLimit":"0.184"},{"groupIds":["OG001","OG002"],"groupDescription":"Dengue Virus Serotype 3: Phase III Lot 2 vs Lot 3","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.042","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.167","ciUpperLimit":"0.082"},{"groupIds":["OG000","OG002"],"groupDescription":"Dengue Virus Serotype 3: Phase III Lot 3 vs Lot 1","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.016","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.144","ciUpperLimit":"0.113"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 4: Phase III Lot 1 vs Lot 2","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.144","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.006","ciUpperLimit":"0.295"},{"groupIds":["OG001","OG002"],"groupDescription":"Dengue Virus Serotype 4: Phase III Lot 2 vs Lot 3","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.060","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.207","ciUpperLimit":"0.088"},{"groupIds":["OG000","OG002"],"groupDescription":"Dengue Virus Serotype 4: Phase III Lot 3 vs Lot 1","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.085","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.242","ciUpperLimit":"0.073"}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine","description":"GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using PRNT assay. Equivalence of Phase III vaccine with Phase II vaccine was assessed by Bridging between Phase III and Phase II Lot of CYD Dengue Vaccine.","populationDescription":"Analysis was performed on Per Protocol Analysis Set. Here, 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for placebo.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer (1/dilution)","timeFrame":"28 days post-Injection 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Pooled Phase III Lot","description":"Participants received 3 doses of CYD dengue vaccine one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3) from any of the Phase III Lots 1, 2 or 3."},{"id":"OG001","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"128"}]}],"classes":[{"title":"Dengue Virus Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","lowerLimit":"16.5","upperLimit":"20.9"},{"groupId":"OG001","value":"15.1","lowerLimit":"12.4","upperLimit":"18.4"}]}]},{"title":"Dengue Virus Serotype 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","lowerLimit":"47.2","upperLimit":"65.1"},{"groupId":"OG001","value":"25.7","lowerLimit":"20.6","upperLimit":"32"}]}]},{"title":"Dengue Virus Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","lowerLimit":"62.4","upperLimit":"79.1"},{"groupId":"OG001","value":"83.6","lowerLimit":"71.1","upperLimit":"98.4"}]}]},{"title":"Dengue Virus Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.9","lowerLimit":"96.1","upperLimit":"127.9"},{"groupId":"OG001","value":"115.4","lowerLimit":"92.8","upperLimit":"143.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 1","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.091","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.009","ciUpperLimit":"0.192"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 2","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"0.334","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.202","ciUpperLimit":"0.466"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 3","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.076","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.173","ciUpperLimit":"0.021"},{"groupIds":["OG000","OG001"],"groupDescription":"Dengue Virus Serotype 4","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was \\> -0.301 and the upper limit was \\< 0.301.","paramType":"Difference of Log10 GMT","paramValue":"-0.017","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.137","ciUpperLimit":"0.103"}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Injection Site Reactions After Any Vaccination","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Pain: Grade 3: Significant; prevents daily activity. Erythema and Swelling: Grade 3: \\> 10 cm. Participants with Injection Site Reactions of any Grade (1, 2 or 3) and grade 3 were reported.","populationDescription":"Analysis was performed on Safety Analysis Set which included all participants who received the study dose, and participants were analyzed according to the treatment received. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post any vaccination","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG003","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG004","title":"Placebo","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"164"},{"groupId":"OG003","value":"167"},{"groupId":"OG004","value":"57"}]}],"classes":[{"title":"Pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"78"},{"groupId":"OG004","value":"11"}]}]},{"title":"Pain: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Erythema: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"0"}]}]},{"title":"Erythema: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"}]}]},{"title":"Swelling: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Systemic Reactions After Any Vaccination","description":"Solicited systemic reactions: Asthenia, Fever, Headache, Malaise and Myalgia. Fever: Grade 3: \\>=39.0°C (\\>=102.1°F). Headache, malaise, myalgia and asthenia: Grade 3: significant; prevents daily activity. Participants with systemic reactions of any Grade (1, 2 or 3) and grade 3 were reported.","populationDescription":"Analysis was performed on Safety Analysis Set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"14 days post any vaccination","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG003","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0(vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."},{"id":"OG004","title":"Placebo","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"164"},{"groupId":"OG003","value":"167"},{"groupId":"OG004","value":"57"}]}],"classes":[{"title":"Asthenia: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"20"}]}]},{"title":"Asthenia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"}]}]},{"title":"Fever: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"}]}]},{"title":"Fever: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"108"},{"groupId":"OG003","value":"104"},{"groupId":"OG004","value":"28"}]}]},{"title":"Headache: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"}]}]},{"title":"Malaise: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"97"},{"groupId":"OG003","value":"90"},{"groupId":"OG004","value":"26"}]}]},{"title":"Malaise: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"3"}]}]},{"title":"Myalgia: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"84"},{"groupId":"OG004","value":"21"}]}]},{"title":"Myalgia: Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"164"},{"groupId":"OG004","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 28 days after each dose of CYD dengue vaccine or Placebo. Solicited Reaction (SR) data were collected within 7 and 14 days after each vaccination. Serious adverse event (SAE) data were collected throughout the study, up to 30 days post-vaccination 3 (up to Month 13).","description":"Analysis was performed on Safety Analysis Set.","eventGroups":[{"id":"EG000","title":"CYD Dengue Vaccine Phase III Lot 1","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","deathsNumAffected":0,"deathsNumAtRisk":163,"seriousNumAffected":10,"seriousNumAtRisk":163,"otherNumAffected":136,"otherNumAtRisk":163},{"id":"EG001","title":"CYD Dengue Vaccine Phase III Lot 2","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","deathsNumAffected":0,"deathsNumAtRisk":161,"seriousNumAffected":9,"seriousNumAtRisk":161,"otherNumAffected":131,"otherNumAtRisk":161},{"id":"EG002","title":"CYD Dengue Vaccine Phase III Lot 3","description":"Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","deathsNumAffected":0,"deathsNumAtRisk":164,"seriousNumAffected":5,"seriousNumAtRisk":164,"otherNumAffected":135,"otherNumAtRisk":164},{"id":"EG003","title":"CYD Dengue Vaccine Phase II Lot","description":"Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","deathsNumAffected":0,"deathsNumAtRisk":167,"seriousNumAffected":9,"seriousNumAtRisk":167,"otherNumAffected":140,"otherNumAtRisk":167},{"id":"EG004","title":"Placebo","description":"Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.","deathsNumAffected":0,"deathsNumAtRisk":57,"seriousNumAffected":1,"seriousNumAtRisk":57,"otherNumAffected":41,"otherNumAtRisk":57}],"seriousEvents":[{"term":"Stress Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pancreatitis Acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Bartholin's Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Groin Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Skin Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Foreign Body","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Ligament Rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Muscle Rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Diabetic Ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Type 2 Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Haemarthrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Intervertebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Polymyalgia Rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Hypergammaglobulinaemia Benign Monoclonal","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Malignant Melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Malignant Melanoma In Situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Prostate Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Calculus Ureteric","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Pelvic Pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":161},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":164},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]}],"otherEvents":[{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":163},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":161},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":164},{"groupId":"EG003","numEvents":4,"numAffected":1,"numAtRisk":167},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":57}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":49,"numAtRisk":163},{"groupId":"EG001","numEvents":72,"numAffected":51,"numAtRisk":161},{"groupId":"EG002","numEvents":74,"numAffected":58,"numAtRisk":164},{"groupId":"EG003","numEvents":90,"numAffected":69,"numAtRisk":167},{"groupId":"EG004","numEvents":26,"numAffected":20,"numAtRisk":57}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":163},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":161},{"groupId":"EG002","numEvents":31,"numAffected":25,"numAtRisk":164},{"groupId":"EG003","numEvents":32,"numAffected":24,"numAtRisk":167},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":57}]},{"term":"Injection Site Haematoma","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":163},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":161},{"groupId":"EG002","numEvents":13,"numAffected":12,"numAtRisk":164},{"groupId":"EG003","numEvents":10,"numAffected":10,"numAtRisk":167},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":57}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":73,"numAtRisk":163},{"groupId":"EG001","numEvents":114,"numAffected":74,"numAtRisk":161},{"groupId":"EG002","numEvents":122,"numAffected":73,"numAtRisk":164},{"groupId":"EG003","numEvents":122,"numAffected":78,"numAtRisk":167},{"groupId":"EG004","numEvents":15,"numAffected":11,"numAtRisk":57}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":110,"numAffected":72,"numAtRisk":163},{"groupId":"EG001","numEvents":116,"numAffected":75,"numAtRisk":161},{"groupId":"EG002","numEvents":146,"numAffected":97,"numAtRisk":164},{"groupId":"EG003","numEvents":126,"numAffected":90,"numAtRisk":167},{"groupId":"EG004","numEvents":43,"numAffected":26,"numAtRisk":57}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":163},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":161},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":164},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":167},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":163},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":161},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":164},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":167},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":57}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":163},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":161},{"groupId":"EG002","numEvents":18,"numAffected":16,"numAtRisk":164},{"groupId":"EG003","numEvents":15,"numAffected":14,"numAtRisk":167},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":57}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":100,"numAffected":70,"numAtRisk":163},{"groupId":"EG001","numEvents":105,"numAffected":69,"numAtRisk":161},{"groupId":"EG002","numEvents":111,"numAffected":72,"numAtRisk":164},{"groupId":"EG003","numEvents":124,"numAffected":84,"numAtRisk":167},{"groupId":"EG004","numEvents":30,"numAffected":21,"numAtRisk":57}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":188,"numAffected":103,"numAtRisk":163},{"groupId":"EG001","numEvents":186,"numAffected":97,"numAtRisk":161},{"groupId":"EG002","numEvents":208,"numAffected":108,"numAtRisk":164},{"groupId":"EG003","numEvents":201,"numAffected":104,"numAtRisk":167},{"groupId":"EG004","numEvents":61,"numAffected":28,"numAtRisk":57}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":163},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":161},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":164},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":167},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":57}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":163},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":161},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":164},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":167},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":57}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra version 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":163},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":161},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":164},{"groupId":"EG003","numEvents":13,"numAffected":12,"numAtRisk":167},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":57}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi Pasteur","email":"Contact-US@sanofi.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"},{"id":"D019595","term":"Severe Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]}},"hasResults":true}